BNU

Novadip Biosciences SA Announces First Pediatric Patient with Congenital Pseudoarthrosis of the Tibia Undergoes Implantation with NVD-003, an Autologous Tissue Regeneration Product, in Phase 1b/2a US/EU Clinical Trial

Retrieved on: 
Wednesday, May 17, 2023

The patient was treated at the Saint-Luc University Hospital in Brussels by Dr. Pierre-Louis Docquier, EU principal investigator for this study.

Key Points: 
  • The patient was treated at the Saint-Luc University Hospital in Brussels by Dr. Pierre-Louis Docquier, EU principal investigator for this study.
  • Dr. Docquier has considerable clinical experience using ASC-based therapies generated from Novadip’s 3M3 tissue regeneration platform in clinical and compassionate use settings.
  • The Phase 1b/2a trial will enroll four CPT patients between two and eight years of age in the US and EU.
  • The primary endpoint of the study is short-term safety of NVD-003 up to 12 months following grafting surgery (GS).

Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma

Retrieved on: 
Thursday, December 8, 2022

Highlights from the clinical study results include:

Key Points: 
  • Highlights from the clinical study results include:
    The results demonstrate NVD-003s ability to reverse severe bone deterioration and to achieve accelerated ossification.
  • A total of eight patients (89%) presented clinical healing during the two years of follow-up post-GS.
  • All patients achieved total weight bearing at six months and seven patients (78%) were walking normally at 2 years.
  • The studys primary endpoint was safety of NVD003 in adult patients with recalcitrant lower limb non-union.

Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million

Retrieved on: 
Thursday, November 3, 2022

Novadip Biosciences (Novadip or the Company), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, today announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive funding.

Key Points: 
  • Novadip Biosciences (Novadip or the Company), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, today announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive funding.
  • The EUR 40 million financing is comprised of EUR 24 million in new equity and EUR 16 million in non-dilutive financing mainly by the Walloon Region.
  • We have been enormously impressed with the progress the Novadip team has achieved in advancing the 3MAUTO and 3MALLO programs into clinical studies.
  • If NVD-003 is approved by the FDA, Novadip is eligible to receive a priority review voucher that could provide more than $100 million revenue.

ByteNext's Metaverse Vision Started with Its Layer 6

Retrieved on: 
Thursday, November 25, 2021

Initiating the NFT-centric Ecosystem with AvatarArt Marketplace

Key Points: 
  • Hanoi, Vietnam--(Newsfile Corp. - November 25, 2021) - ByteNexts Metaverse vision started with Layer 6.
  • It appears that the thesis - Games are not just game but the world - has eventually come true.
  • NFT Games now has the stepping stone to bring the real world into the Metaverse.
  • ByteNext is a blockchain incubation hub on a mission to realize the full-scale Metaverse Economy.

Visitors Flock to Popular 2021 Sands Shopping Carnival

Retrieved on: 
Monday, August 2, 2021

MACAU, Aug. 2, 2021 /PRNewswire/ --The 2021 Sands Shopping Carnival successfully concluded July 25 at The VenetianMacao, after attracting more than 110,000 visits with three days of shopping, activities and entertainment.

Key Points: 
  • MACAU, Aug. 2, 2021 /PRNewswire/ --The 2021 Sands Shopping Carnival successfully concluded July 25 at The VenetianMacao, after attracting more than 110,000 visits with three days of shopping, activities and entertainment.
  • It provided a free business platform for local SMEsand Sands retailers amid the pandemic period and offered an exciting weekend destination for local residents and tourists.
  • Sands China targeted Macao retailers, including local micro-small-and-medium enterprises, as exhibitors, with all enjoying free registration and booths.
  • Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

3-Day Sands Shopping Carnival Now Open at Cotai Expo - Free Admission

Retrieved on: 
Friday, July 23, 2021

The popular weekend shopping and leisure hotspot is back for a second year, after last year's inaugural event welcomed more than 100,000 visitors.

Key Points: 
  • The popular weekend shopping and leisure hotspot is back for a second year, after last year's inaugural event welcomed more than 100,000 visitors.
  • Besides keeping booths free for exhibitors, Sands China added 10 per cent more booths this year, totalling over 560.
  • The Company's Cotai Strip portfolio has the goal of contributing to Macao's transformation into a world centre of tourism and leisure.
  • Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

Bright Scholar Announces the Opening of Huiyan International Education College of Beijing Normal University

Retrieved on: 
Wednesday, November 21, 2018

FOSHAN, China, Nov. 21, 2018 /PRNewswire/ -- Bright Scholar Education Holdings Limited ("Bright Scholar" or the "Company") (NYSE: BEDU), the largest operator of international and bilingual K-12 schools in China*, in collaboration with Beijing Normal University ("BNU"), today jointly announced the opening of Huiyan International Education College (the "College").

Key Points: 
  • FOSHAN, China, Nov. 21, 2018 /PRNewswire/ -- Bright Scholar Education Holdings Limited ("Bright Scholar" or the "Company") (NYSE: BEDU), the largest operator of international and bilingual K-12 schools in China*, in collaboration with Beijing Normal University ("BNU"), today jointly announced the opening of Huiyan International Education College (the "College").
  • Hongpei Sun, Deputy Party Secretary of Beijing Normal University, Hongguang Cheng, Division Head of Office of International Exchange & Cooperation of Beijing Normal University, Wulong Zhang, Secretary-General of Beijing Normal University Education Foundation, Xudong Zhu, Dean of Faculty of Education of Beijing Normal University, Huiyan Yang, Chairlady of Bright Scholar, Jerry He, CEO of Bright Scholar, Jinsheng Cheng, Vice President of School Operation of Bright Scholar, and Shu Chen, Vice President of Strategic Alliances of Bright Scholar attended the opening ceremony.
  • The Chairlady continued her comments, "The collaboration between Beijing Normal University and Bright Scholar in the establishment of Huiyan International Education College will focus on various areas, first the College will collaborate with overseas universities to introduce renowned education institution brands and resources into China.
  • Our goal is to develop outstanding education professionals and establish Huiyan International Education College as a world-class international education college."